. Author manuscript; available in PMC: 2009 Apr 1.

Published in final edited form as: Eur J Pharm Sci. 2008 Jan 31;33(4-5):371–379. doi: 10.1016/j.ejps.2008.01.006

Table 2.

Pharmacokinetic parameters of 6-β-naltrexol (NTXOL) after application of a gel formulation containing either CB-NTXOL-BUPOH or 6-β-naltrexol base (control). Data is represented as mean (±S.D.). n = 5 for NTXOL and n = 6 for CB-NTXOL-BUPOH

Parameter	NTXOL	NTXOL from CB-NTXOL-BUPOH
AUC_0-48(ng/ml^*h)	66.4 ± 7.9	282.0 ± 14.5
C_max(ng/ml)	1.5 ± 0.2	6.6 ± 0.4
T_max (h)	28.1 ± 1.5	10.1 ± 0.9
T_lag (h)	5.1 ± 0.7	5.0 ± 1.1
Observed C_SS(ng/ml)	1.3 ± 0.5	6.4 ± 0.9
Predicted C_SS(ng/ml)^*	0.2 ± 0.1	0.7 ± 0.3
Enhancement factor	1	5.3

Predicted from in vitro human skin diffusion data